Delta3, fthma-070, tango85, tango77, spoil, neokine, tango129, and integrin alpha subunit protein and nucleic acid molecules and uses thereof

Abstract

The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

1 - 12 . (canceled) 
     
     
         13 . An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3; b) a nucleic acid molecule comprising a fragment of at least 500 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2; and e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions. 
     
     
         14 . The isolated nucleic acid molecule of  claim 13 , further comprising a fragment of at least 1000 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. 
     
     
         15 . The isolated nucleic acid molecule of  claim 13 , further comprising a fragment of at least 1500 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. 
     
     
         16 . The isolated nucleic acid molecule of  claim 13 , further comprising a fragment of at least 2000 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. 
     
     
         17 . The isolated nucleic acid molecule of  claim 13 , which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2. 
     
     
         18 . The isolated nucleic acid molecule of  claim 13 , which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 200 contiguous amino acids of SEQ ID NO:2. 
     
     
         19 . The isolated nucleic acid molecule of  claim 13 , which is selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; and b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         20 . The nucleic acid molecule of  claim 13  further comprising vector nucleic acid sequences. 
     
     
         21 . The nucleic acid molecule of  claim 13  further comprising nucleic acid sequences encoding a heterologous polypeptide. 
     
     
         22 . A host cell which contains the nucleic acid molecule of  claim 13 . 
     
     
         23 . The host cell of  claim 22  which is a mammalian host cell. 
     
     
         24 . A non-human mammalian host cell containing the nucleic acid molecule of  claim 13 . 
     
     
         25 . An isolated polypeptide selected from the group consisting of: a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or a complement thereof; b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3; and c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2. 
     
     
         26 . The isolated polypeptide of  claim 25 , comprising a fragment which comprises at least 100 contiguous amino acids of SEQ ID NO:2. 
     
     
         27 . The isolated polypeptide of  claim 25 , comprising a fragment which comprises at least 200 contiguous amino acids of SEQ ID NO:2. 
     
     
         28 . The isolated polypeptide of  claim 25 , comprising a fragment which comprises at least 500 contiguous amino acids of SEQ ID NO:2. 
     
     
         29 . The isolated polypeptide of  claim 25 , comprising a fragment which is at least 90% homologous to the amino acid sequence of SEQ ID NO:2. 
     
     
         30 . The isolated polypeptide of  claim 25 , comprising a fragment which is at least 95% homologous to the amino acid sequence of SEQ ID NO:2. 
     
     
         31 . The isolated polypeptide of  claim 25 , comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         32 . The isolated polypeptide of  claim 25  further comprising heterologous amino acid sequences. 
     
     
         33 . An antibody which selectively binds to a polypeptide of  claim 25 . 
     
     
         34 . The antibody of  claim 33 , which is a monoclonal antibody. 
     
     
         35 . The antibody of  claim 34 , comprising an immunologically active portion selected from the group consisting of: a) an scFV fragment; b) a dcFV fragment; c) an Fab fragment; and d) an F(ab′).sub.2 fragment. 
     
     
         36 . The antibody of  claim 34 , wherein the antibody is selected from the group consisting of: a) a chimeric antibody; b) a humanized antibody; c) a human antibody; d) a non-human antibody; and e) a single chain antibody. 
     
     
         37 . A method for producing a polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2; b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2; c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, or a complement thereof under stringent conditions; comprising culturing the host cell of  claim 22  under conditions in which the nucleic acid molecule is expressed. 
     
     
         38 . A method for detecting the presence of a polypeptide of  claim 25  in a sample, comprising: contacting the sample with a compound which selectively binds to a polypeptide of  claim 25 ; and determining whether the compound binds to the polypeptide in the sample. 
     
     
         39 . The method of  claim 38 , wherein the compound which binds to the polypeptide is an antibody. 
     
     
         40 . A kit comprising a compound which selectively binds to a polypeptide of  claim 25  and instructions for use. 
     
     
         41 . A method for detecting the presence of a nucleic acid molecule of  claim 13  in a sample, comprising the steps of: contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample. 
     
     
         42 . The method of  claim 41 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe. 
     
     
         43 . A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of  claim 13  and instructions for use. 
     
     
         44 . A method for identifying a compound which binds to a polypeptide of  claim 25  comprising the steps of: contacting a polypeptide, or a cell expressing a polypeptide of  claim 25  with a test compound; and determining whether the polypeptide binds to the test compound. 
     
     
         45 . The method of  claim 44 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: a) detection of binding by direct detecting of test compound/polypeptide binding; b) detection of binding using a competition binding assay; and c) detection of binding using an assay for Delta3-mediated signal transduction. 
     
     
         46 . A method for modulating the activity of a polypeptide of  claim 25  comprising contacting a polypeptide or a cell expressing a polypeptide of  claim 25  with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide. 
     
     
         47 . A method for identifying a compound which modulates the activity of a polypeptide of  claim 25 , comprising: contacting a polypeptide of  claim 25  with a test compound; and determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide. 
     
     
         48 . An isolated antibody, or portion thereof, that specifically binds to a polypeptide selected from the group consisting of: a) the polypeptide comprising the amino acid sequence of SEQ ID NO:2; b) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 3; and c) the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 98348. 
     
     
         49 . The antibody, or portion thereof, of  claim 48 , wherein said antibody specifically binds to the polypeptide comprising the amino acid sequence of SEQ ID NO:2. 
     
     
         50 . The antibody, or portion thereof, of  claim 48 , wherein said antibody specifically binds to the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 3. 
     
     
         51 . The antibody, or portion thereof, of  claim 48 , wherein said antibody specifically binds to the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 98348. 
     
     
         52 . The antibody, or portion thereof, of  claim 48 , wherein said antibody is selected from the group consisting of: i) a monoclonal antibody; ii) a polyclonal antibody; iii) a bispecific antibody; and iii) a chimeric antibody. 
     
     
         53 . The antibody, or portion thereof, of  claim 48 , wherein said portion is a F(ab) fragment or a F(ab′).sub.2 fragment. 
     
     
         54 . The antibody, or portion thereof, of  claim 48 , wherein said antibody binds to amino acid residues 18-529 of SEQ ID NO:2. 
     
     
         55 . The antibody, or portion thereof, of  claim 48 , wherein said antibody is detectably labeled. 
     
     
         56 . The antibody, or portion thereof, of  claim 55 , wherein the detectable label is selected from the group consisting of: a) an enzyme; b) a fluorescent material; c) a luminescent material; d) a bioluminescent material; and e) a radioactive material.